- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Officials at NanCogenics, Inc. announced today that Co-Founder Dr. Jim Klostergaard has been invited to present at the upcoming BioNanoMed 4th International Conference on Nanotechnology, Medicine and Biology, to be held March 13-15, in Krems, Austria. Dr. Klostergaard will speak about a paper titled "A Cancer Treatment Modality Based on the Tumor-Specific Localization of Cancer Therapeutics", which will discuss the application of the company's tumor targeting platform as a clinical procedure.
This prestigious three day congress will bring together academia, industry, governmental and non-governmental institutions to discuss current, emerging and future trends of the converging fields of Nanotechnology, Biotechnology and Medicine. The theme for BioNanoMed 2013 is Nanotechnology Enables Personalized Medicine which focuses on current and developing efforts to bring an individualized approach to cancer therapy.
The NanCogenics technology platform, as envisioned by Co-Founders, Dr. Klostergaard, Professor of Molecular and Cellular Oncology at the University of Texas M D Anderson Cancer Center (Houston, TX), and Charles Seeney, Managing Director of NewTech Development (Edmond, OK), enables the emerging trend to personalized medicine. The nanotechnology-based platform is based on designed therapeutic nano prodrug constructs that respond to external magnetic forces in targeting tumor sites, generating effective anti-tumor results without harm to normal tissue or organs, thereby substantially reducing the feared side effects and complications often attributed to chemotherapy. The Co-Founders believe that the advancement of this platform to the clinic will lead to significant improvements, not only in cancer chemotherapy, but also as a means of targeting a range of new cancer therapeutics now under development.
The Company's newly recruited President and CEO, states that "this conference provides a significant first step in our efforts to raise the awareness of the potential of magnetic localization, and the impact NanCogenics can have in the emerging field of nanomedicine". He further states that the Company is moving forward with funding mechanisms to support business objectives and anticipated future FDA IND filings.
About NanCogenics, Inc.
Overall, NanCogenics sees itself as a resource for enhanced and improved therapeutic performance, with more drug penetration occurring at the target site and less to normal tissue. The capacity to localize cytotoxic drugs in high concentrations at the tumor site will lead to more effective treatment regimens, greater patient compliance to therapy and improved outcomes, such as patient quality of life and survival rates.
Safe Harbor Statement
Certain statement included in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of products and services, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. The company's expectations regarding future revenues are dependent upon the ability to develop and supply products and services that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions are generally considered forward-looking statements. These statements reflect current expectations.
For more information, please click here
Copyright © NanCogenics, Inc.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
European Technology Platform for Nanomedicine and ENATRANS European Consortium Launch the 2nd edition of the Nanomedicine Award: The Award to be presented at BIO-Europe conference in Munich, November 2015 July 30th, 2015
Take a trip through the brain July 30th, 2015
Sol-gel capacitor dielectric offers record-high energy storage July 30th, 2015
BESSTECH Names Doug Grose as Chief Technology Officer: Former GLOBALFOUNDRIES CEO to drive technology roadmap and strategic partnerships for emerging lithium-ion battery component company July 14th, 2015
A cool way to form 2-D conducting polymers using ice: POSTECH scientists develop breakthrough technique to easily optimize electrical properties of Polyaniline nanosheets to an unprecedented level in an environmental-friendly and inexpensive way July 7th, 2015
March 2016; 6th Int'l Conference on Nanostructures in Iran July 29th, 2015
Nanometrics Announces Upcoming Investor Events July 28th, 2015